Treatments for Alzheimer's disease emerge
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Anti-amyloid immunotherapies will provide the first disease-modifying therapeutics
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The recent approval by the US Federal Drug Administration (FDA) of a disease‐modifying drug, aducanumab 151 , has been seen as a major milestone 152 .”
From Mental health care for older adults: recent advances and new directions in clinical practice and research (2022) · cites this paper as [152]
In the citing paper
“Aducanumab may be the first of several disease‐modifying drugs coming to the clinic, and has generated renewed interest in drug treatment of Alzheimer's disease and other dementias.”
From Mental health care for older adults: recent advances and new directions in clinical practice and research (2022) · cites this paper as [152]
In the citing paper
“Donepezil, galantamine, and rivastigmine are the cholinesterase inhibitors that are most frequently prescribed [102,103,104,105,106].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [104]
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Self-citationJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Fischl, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Schooley, R. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170401 · Cited by 2,995
The Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728
Monetary Costs of Dementia in the United States
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1204629 · Cited by 1,484
Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242
ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Initiative, A. D. N., Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., et al. (2017) · Nature · doi:10.1038/nature24016 · Cited by 1,220
Cited by
2022 Alzheimer's disease facts and figures
(2022) · Alzheimer's & Dementia · doi:10.1002/alz.12638 · Cited by 2,341
Reynolds, C. F., Jeste, D. V., Sachdev, P. S., & Blazer, D. G. (2022) · World Psychiatry · doi:10.1002/wps.20996 · Cited by 465
Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders
Brandebura, A. N., Paumier, A., Onur, T. S., & Allen, N. J. (2023) · Nature Reviews Neuroscience · doi:10.1038/s41583-022-00641-1 · Cited by 427
The China Alzheimer Report 2022
Ren, R., Qi, J., Lin, S., Liu, X., Yin, P., Wang, Z., Tang, R., Wang, J., Huang, Q., Li, J., et al. (2022) · General Psychiatry · doi:10.1136/gpsych-2022-100751 · Cited by 353
Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis
Lecca, D., Jung, Y. J., Scerba, M. T., Hwang, I., Kim, Y. K., Kim, S., Modrow, S., Tweedie, D., Hsueh, S., Liu, D., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12610 · Cited by 218
Nanotechnology for enhanced nose-to-brain drug delivery in treating neurological diseases
Huang, Q., Chen, Y., Zhang, W., Xia, X., Li, H., Qin, M., & Gao, H. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.054 · Cited by 167
Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Fedele, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914499 · Cited by 102
Villain, N., Planche, V., & Levy, R. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.06.012 · Cited by 87
Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease
Rabinovici, G. D., & La Joie, R. (2023) · JAMA · doi:10.1001/jama.2023.11703 · Cited by 80
Huang, Q., Jiang, C., Xia, X., Wang, Y., Yan, C., Wang, X., Lei, T., Yang, X., Yang, W., Cheng, G., et al. (2023) · Research · doi:10.34133/research.0180 · Cited by 78
Luo, J., Beam, C. R., & Gatz, M. (2023) · Prevention Science · doi:10.1007/s11121-022-01385-1 · Cited by 65
“The first diseasemodifying treatment for Alzheimer’s disease (AD), which is the most common cause of dementia, has just been approved by the US Food and Drug Administration, albeit with conditions for use and based on mixed evidence (Selkoe, 2021).”
BackgroundWang, R., Chopra, N., Nho, K., Maloney, B., Obukhov, A. G., Nelson, P. T., Counts, S. E., & Lahiri, D. K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01351-3 · Cited by 66
“Unfortunately, conventional drug therapies targeting these proteins have had limited success due to a variety of factors 3, 16, 36 .”
Natural Polyphenolic Nanodots for Alzheimer's Disease Treatment
Yang, P., Huang, Q., Zhang, J., Li, Y., Gao, H., & Gu, Z. (2023) · Advanced Materials · doi:10.1002/adma.202308393 · Cited by 74
Yin, H., Ju, Z., Zheng, M., Zhang, X., Zuo, W., Wang, Y., Ding, X., Zhang, X., Peng, Y., Li, J., et al. (2023) · PLOS Biology · doi:10.1371/journal.pbio.3002017 · Cited by 62
Liu, P., Zhou, Y., Shi, J.-Z., Wang, F., Yang, X., Zheng, X., Wang, Y., He, Y., Xie, X., & Pang, X. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154801 · Cited by 71
Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56
Testosterone, cognitive decline and dementia in ageing men
Yeap, B. B., & Flicker, L. A. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09728-7 · Cited by 62
Ni, H., Liao, Y., Zhang, Y., Lu, H., Huang, Z., Huang, F., Zhang, Z., Dong, Y., Wang, Z., & Huang, Y. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110783 · Cited by 53
Zhang, S., Lv, S., Li, Y., Wei, D., Zhou, X., Niu, X., Yang, Z., Song, W., Zhang, Z., & Peng, D. (2023) · European Journal of Nutrition · doi:10.1007/s00394-023-03208-7 · Cited by 44
Huang, Z., Merrihew, G. E., Larson, E. B., Park, J., Plubell, D., Fox, E. J., Montine, K. S., Latimer, C. S., Dirk Keene, C., Zou, J. Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38376-x · Cited by 37
“In contrast, emerging agents like mAb158, also called BAN2401 or Lecanemab, binds to soluble A β species and has shown promising outcomesininitialclinicaltrials 28 .”
Oumata, N., Lu, K., Teng, Y., Cavé, C., Yu, P., Galons, H., & Roques, B. P. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114578 · Cited by 38
Turquoise killifish: A natural model of age-dependent brain degeneration
de Bakker, D. E. M., & Valenzano, D. R. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102019 · Cited by 39
“The age-dependent decrease in cognitive ability dramatically decreases the quality of life for patients and is used as a key phenotypic output in studies seeking to alleviate the effects of neurodegenerative disorders (Selkoe, 2021; van Dyck et al., 2022).”
BackgroundHumanin and Alzheimer's disease: The beginning of a new field
Niikura, T. (2021) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2021.130024 · Cited by 35
Boosting mitochondrial health to counteract neurodegeneration
Burtscher, J., Romani, M., Bernardo, G., Popa, T., Ziviani, E., Hummel, F. C., Sorrentino, V., & Millet, G. P. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102289 · Cited by 37
“They may, for instance, improve the outcome of the revolutionizing amyloidogenic protein removing strategies (Alexander et al., 2021; Kwon et al., 2020; Selkoe, 2021).”
BackgroundCanet, G., Zussy, C., Hernandez, C., Maurice, T., Desrumaux, C. M., & Givalois, L. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108398 · Cited by 36
Metsla, K., Kirss, S., Laks, K., Sildnik, G., Palgi, M., Palumaa, T., Tõugu, V., & Palumaa, P. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215026 · Cited by 35
“Currently there is conflicting evidence about the clinical benefit of the costly Aducanumab treatment [11].”
Bai, Z., Ge, K., Fu, J., Yu, D., Hua, Z., Xue, S., Li, Z., Sheng, W., Wu, X., Gao, F., et al. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.142955 · Cited by 29
Versatile nanomaterials for Alzheimer’s disease: Pathogenesis inspired disease-modifying therapy
Xi, Y., Chen, Y., Jin, Y., Han, G., Song, M., Song, T., Shi, Y., Tao, L., Huang, Z., Zhou, J., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.034 · Cited by 27
Kundu, P., Stagaman, K., Kasschau, K. D., Holden, S. J., Shulzhenko, N., Sharpton, T. J., & Raber, J. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.791128 · Cited by 24
“…of association between the abundance of individual microbial taxa and both mouse behavioral scores and genotype using compound Poisson generalized linear regression (Sharpton et al., 2017) to appropriately model the over-dispersion and zero-inflation often observed in microbiome count data.”
MethodAmyloid-β in Alzheimer’s disease – front and centre after all?
Weglinski, C., & Jeans, A. F. (2023) · Neuronal Signaling · doi:10.1042/ns20220086 · Cited by 26
Amano, A., Sanjo, N., Araki, W., Anraku, Y., Nakakido, M., Matsubara, E., Tomiyama, T., Nagata, T., Tsumoto, K., Kataoka, K., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01772-y · Cited by 29
Sanotra, M. R., Kao, S., Lee, C., Hsu, C.-H., Huang, W., Chang, T.-C., Tu, F.-Y., Hsu, I.-U. Y., & Lin, Y. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01261-2 · Cited by 23
Grossmann, K. (2022) · Biomedicines · doi:10.3390/biomedicines10081890 · Cited by 26
Zhu, Z., Liao, L., & Qiao, H. (2022) · Acupuncture and Herbal Medicine · doi:10.1097/hm9.0000000000000039 · Cited by 26
“Immunotherapies against Aβ and tau proteins are in the advanced stages of clinical trials and have the potential to block the progression of AD[25].”
BackgroundNanotechnology-based gene therapy as a credible tool in the treatment of Alzheimer’s disease
Unnisa, A., Greig, N. H., & Kamal, M. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.369096 · Cited by 24
Nuthakki, V. K., Choudhary, S., Reddy, C. N., Bhatt, S., Jamwal, A., Jotshi, A., Raghuvanshi, R., Sharma, A., Thakur, S., Jadhav, H. R., et al. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00030 · Cited by 25
Zhang, N., Nao, J., & Dong, X. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c06672 · Cited by 25
Liu, L., Liu, W., Sun, Y. P., & Dong, X. (2024) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2024.05.193 · Cited by 22
Luo, J. J., Wallace, W., & Kusiak, J. W. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120294 · Cited by 17
Kreutzer, A. G., Parrocha, C. M. T., Haerianardakani, S., Guaglianone, G., Nguyen, J. T., Diab, M. N., Yong, W. H., Perez-Rosendahl, M. A., Head, E., & Nowick, J. S. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00592 · Cited by 21
Sanotra, M. R., Huang, W., Silver, S. D., Lin, C., Chang, T.-C., Nguyen, D. P. Q., Lee, C., Kao, S., Shieh, J. C.-C., & Lin, Y. (2021) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2021.12.005 · Cited by 19
Fallacies in Neuroscience: The Alzheimer's Edition
Herrup, K. (2022) · eNeuro · doi:10.1523/eneuro.0530-21.2021 · Cited by 18
“Despite a string of new publications arguing for the continued value of the amyloid cascade hypothesis (for review, see Selkoe, 2021), novel and exciting nonamyloid alternatives are increasingly being developed and tested, even as anti-tau and anti-amyloid treatments remain a significant part of…”
BackgroundPutative Structures of Membrane-Embedded Amyloid β Oligomers
Sepehri, A., & Lazaridis, T. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00535 · Cited by 18
Mechanism of anti-AD action of OAB-14 by enhancing the function of glymphatic system
Zhang, X., Cao, R., Zhu, C., Yang, L., Zheng, N., Ji, W., Liu, P., Chi, T., Ji, X., Zheng, Z., et al. (2023) · Neurochemistry International · doi:10.1016/j.neuint.2023.105633 · Cited by 15
Meldolesi, J. (2022) · Biomedicines · doi:10.3390/biomedicines10010105 · Cited by 17
“Antibodies that target these proteins are in advanced stages of clinical trial [9].”
BackgroundInfluentialWang, R., & Lahiri, D. K. (2022) · Scientific Reports · doi:10.1038/s41598-022-05164-4 · Cited by 18
Chatanaka, M. K., Sohaei, D., Diamandis, E. P., & Prassas, I. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2187342 · Cited by 15
Grychowska, K., López-Sánchez, U., Vitalis, M., Canet, G., Satała, G., Olejarz‐Maciej, A., Gołębiowska, J., Kurczab, R., Pietruś, W., Kubacka, M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01482 · Cited by 15
Amyloid-beta Targeted Therapeutic Approaches for Alzheimer’s Disease: Long Road Ahead
Dai, Y., Lei, C., Zhang, Z., Qi, Y., Lao, K., & Gou, X. (2022) · Current Drug Targets · doi:10.2174/1389450123666220421124030 · Cited by 16
Ribaudo, G., Landucci, E., Giannangeli, M., Mazzantini, C., Maccarinelli, G., Mastinu, A., Bonini, S. A., Memo, M., Pellegrini-Giampietro, D. E., & Gianoncelli, A. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15869 · Cited by 15
“Moreover, gantenerumab, a monoclonal antibody that promotes amyloid plaque reductions, was recently approved for the treatment of AD (Salloway et al., 2021; Selkoe, 2021).”
BackgroundAlharbi, K. S., Shaikh, M. A. J., Imam, S. S., Alshehri, S., Ghoneim, M. M., Almalki, W. H., Singh, S. K., Kumar, D., Kumar, A. P., Dua, K., et al. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867330666221122115212 · Cited by 15
Neuroinflammation and nutrition in Alzheimer’s disease
Park, H., Ni, M., & Le, Y. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1622571 · Cited by 17
“…development, such as small molecules (e.g., glutamate modulators, acetylcholinesterase inhibitors) to improve synaptic function and immunotherapy (e.g., anti-A β : lecanemab, donanemab, or anti-β / γ -secretases) to remove plaques and reduce tau tangles, but have had modest success (7, 8, 86, 87).”
The Role of miR-20 in Health and Disease of the Central Nervous System
Arzhanov, I., Sintakova, K., & Romanyuk, N. (2022) · Cells · doi:10.3390/cells11091525 · Cited by 17
Recent Advances in Molecular Dynamics Simulations of Tau Fibrils and Oligomers
Barredo, P. A., & Balanay, M. P. (2023) · Membranes · doi:10.3390/membranes13030277 · Cited by 18
Chen, C., Liu, J., Guo, L., Xiong, F., Ran, X., Guo, Y., Yao, Y., Hao, X., Luo, R., & Zhang, Y. (2022) · Phytochemistry · doi:10.1016/j.phytochem.2022.113392 · Cited by 14
Maccioni, R., Travisan, C., Badman, J., Zerial, S., Wagener, A., Andrade‐Talavera, Y., Picciau, F., Grassi, C., Chen, G., Lemoine, L., et al. (2024) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2024.102585 · Cited by 11
“Recently, A β -immunotherapy showed a positive effect on reducing plaque deposition (Association for the Advancement of Science, 2021; Selkoe, 2021) with the monoclonal antibody Aducanumab, and with the anti-protofibril A β antibody Lecanemab, recently approved by FDA, which reduces both A β…”
Jayatunga, D. P. W., Hone, E., Fernando, W. M. A. D. B., Garg, M. L., Verdile, G., & Martins, R. N. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.781468 · Cited by 12
“Other than the controversies related to very recently approved drug Aducanumab (Selkoe, 2021), the current situation where there is still no AD-targeted-therapy pending approval soon emphasizes the need for identification of AD preventive strategies.”
BackgroundEvaluation of in vivo staging of amyloid deposition in cognitively unimpaired elderly aged 78–94
Michalowska, M. M., Herholz, K., Hinz, R., Amadi, C., McInnes, L., Anton-Rodriguez, J. M., Karikari, T. K., Blennow, K., Zetterberg, H., Ashton, N. J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01685-6 · Cited by 11
Liu, G., & Sun, Y. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251374149 · Cited by 14
An adeno-associated virus-mediated immunotherapy for Alzheimer’s disease
Zhang, Y., Lin, Q., Kuang, Y., Liu, J., Wang, D., Xie, W., Zhang, L., & Fu, L. (2022) · Molecular Immunology · doi:10.1016/j.molimm.2022.02.006 · Cited by 9
Associations of Polygenic Risk Score for Late-Onset Alzheimer's Disease With Biomarkers
Li, Q., Lv, X., Jin, F., Liao, K., Gao, L., & Xu, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.849443 · Cited by 13
“Although aducanumab can reduce the amyloid deposition in the brain and has been approved by Food and Drug Administration to treat Alzheimer’s disease lately, however, controversy about it still exists (Selkoe, 2021; Servick, 2021).”
BackgroundLi, W., Jiang, J., Zou, X., Zhang, Y., Sun, M., Jia, Z., Li, W., & Xu, J. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.961164 · Cited by 15
“However, having limited options for assessing the exact pathophysiology and early diagnosis of AD, the clinical experts are faced with great challenge in providing effective therapeutic strategies (Selkoe, 2021).”
BackgroundDiagnosis and therapy of Alzheimer's disease: Light-driven heterogeneous redox processes
Chen, W., Li, J., Guo, J., Li, L., & Wu, H. (2024) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2024.103253 · Cited by 11
Liu, L., Liu, W., Dong, X., & Sun, Y. P. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.163063 · Cited by 9
Verkhratsky, A., & Butt, A. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821565-4.00012-2 · Cited by 10
Adisa, A. R., Martins, R. N., Bharadwaj, P., Li, Z., Coorey, R., Johnson, S. K., & Fernando, W. M. A. D. B. (2024) · Phytochemistry Reviews · doi:10.1007/s11101-024-09942-y · Cited by 10
“The A b plaques and tau tangles trigger activation of microglia, astrocytes, cellular inflammatory response, and neurotoxicity (Selkoe 2021).”
Ren, H., Tang, L. Y., Yuan, Z., Liu, Y., Zhou, X., Xiao, X., Wu, X., Chen, W., Chen, Y., Wang, H., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1492237 · Cited by 9
“AD is one of the most expensive, lethal, and burdensome diseases of this century, affecting millions of people worldwide (Prince et al., 2015; Scheltens et al., 2021; Selkoe, 2021).”
Bisi, A., Feoli, A., Trezza, A., Viejo, L., Formaggio, F., Bartolini, M., Belluti, F., Gobbi, S., Spiga, O., Caprini, M., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106152 · Cited by 8
Current amyloid inhibitors: Therapeutic applications and nanomaterial-based innovations
López-García, P., Tejero-Ojeda, M. M., Vaquero, M. E., & Carrión‐Vázquez, M. (2025) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2025.102734 · Cited by 8
“Also, they are increasingly gaining relevance due to the fact that unfortunately every advancement in monoclonal antibody-based therapy has shown a general lack of preventive or curative properties in advanced clinical trials (Decourt et al., 2021), with the exception of the recently FDA approved mAb Aducanumab (Selko…”
Zhang, B., Yu, X., & Zhang, X. (2026) · Neurological Sciences · doi:10.1007/s10072-026-08893-w · Cited by 6
“Although several monoclonal antibodies, such as aducanumab, have demonstrated robust amyloid plaque reduction in vivo [ 39], their clinical impact on cognitive outcomes has been inconsistent or marginal [40, 41 ].”
Stögmann, E., & Schmidt, R. (2025) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02466-7 · Cited by 6
“This process potentially mit-igates both direct and downstream negative effects of A β , including tau pathology, and slowing of cognitive decline [5].”
Wu, T., Zhang, X., Cai, S., Zhang, W., & Yang, R. (2024) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2024.114369 · Cited by 7
Shang, D., Song, Y., Cui, Y., Chen, C., Xu, F., Zhu, C., Dong, X., Chen, Y., Wang, S., Li, X., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c16435 · Cited by 5
Li, S., Han, L., Huang, K., Ma, Y.-H., Guo, L., Guo, Y., Ran, X., Yao, Y., Hao, X., Luo, R., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021487 · Cited by 5
Tang, Y., Wang, Y., Gao, Z., Li, J., Zhang, L., Shi, H., Dong, J., Song, S., & Qian, C. (2024) · Chemistry - A European Journal · doi:10.1002/chem.202400870 · Cited by 7
Eichinger, A., Rauth, S., Hinz, D., Feuerbach, A., & Skerra, A. (2022) · Biological Chemistry · doi:10.1515/hsz-2021-0375 · Cited by 7
“…(ii) to construct fusion proteins with protein/peptide ligands of transcytose receptors that enable efficient passage across the blood-brain barrier (BBB) via the Trojan horse strategy, thus effecting neutralization of Aβ peptides within the neuronal tissue from which they originate (Selkoe 2021).”
BackgroundAsih, P. R., Stefanoska, K., Prikas, E., & Ittner, A. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.01.005 · Cited by 5
Van, D. T. T., Hoàng, T. L. H., Trần, T. V. T., Le, T. H., Sơn, L. L., Nguyen, Q. M., Nguyen, T. H. H., Bich, T. T. N., Nguyen, T. H. C., Phan, C. U., et al. (2025) · ACS Omega · doi:10.1021/acsomega.5c05628 · Cited by 4
“1,2 AD, a progressive neurodegenerative disorder, impairs memory, cognition, and daily functioning.”
Lust, B., Flynn, S., Henderson, C., Gair, J. W., & Sherman, J. C. (2023) · Journal of Neurolinguistics · doi:10.1016/j.jneuroling.2023.101190 · Cited by 7
Li, Q., Lv, X., Qian, Q., Liao, K., Du, X., & Initiative, A. D. N. (2024) · Human Brain Mapping · doi:10.1002/hbm.26709 · Cited by 3
“Although aducanumab has been considered a therapeutic drug for AD, controversy remains over the efficacy of the treatment (Selkoe, 2021; Servick, 2021).”
BackgroundAlrouji, M., Yasmin, S., Alshammari, M. S., Alhumaydhi, F. A., Sharaf, S. E., Shahwan, M. J., & Shamsi, A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0316010 · Cited by 6
Joseph, C. R. (2024) · Diagnostics · doi:10.3390/diagnostics14070726 · Cited by 2
“It is clear from these clinical trials, however, that early intervention is necessary for success, perhaps in the preclinical state [9,10].”
BackgroundRamos, J. M. P., Kviatcovsky, D., & Schwartz, M. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15609 · Cited by 3
“…the first new drug for AD in almost 20 years, after the US Food and Drug Administration granted a controversial ‘accelerated approval’ of aducanumab (Figure 1a), based on substantial reduction in Aβ plaques, and with a questionable effect on cognitive decline (Selkoe, 2021; Sevigny et al., 2016).”
BackgroundPhotobiomodulation therapy increases neural stem cell pool in aged 3xTg-AD mice
Johnson, K. J., Johnson, K. M., Grant, A. C., Taglialatela, G., & Micci, M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0321668 · Cited by 3
“However recent developments from long-term follow up studies of anti-Aβ immunotherapy trials have shown modest success in reducing neuropathology and slowing cognitive decline suggesting that early and continuous intervention could yield clinically significant reductions in AD symptoms [8–10].”
ACE1 does not influence cerebral Aβ degradation or amyloid plaque accumulation in 5XFAD mice
Jeon, S., Alia, A. O., Popović, J., Vassar, R. J., & Cuddy, L. K. (2025) · PLoS ONE · doi:10.1371/journal.pone.0330193 · Cited by 3
“Multiple lines of evidence support the relevance of A β deposition and amyloid plaque accumulation in the neurotoxicity and cognitive decline in AD [4,6,7].”
Heise, N. V., Schüler, J., Orlamünde, T. E., Brandes, B., Deigner, H., Al‐Harrasi, A., & Csük, R. (2022) · Mediterranean Journal of Chemistry · doi:10.13171/mjc02211021650csuk · Cited by 2
Lin, Q., Bian, W., Wang, D., Ming, Z., Zhang, Y., Zhang, L., & Fu, L. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221088 · Cited by 2
“Additionally, numerous immunotherapies that only target A (cid:2) or tau have been developed [27].”
InfluentialHu, Y., Xing, S., Huang, Y., Chen, C., Shen, D., & Chen, J. (2023) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207326666230428112358 · Cited by 2
Kumari, P., Sarwa, N., Meena, D., Eesha, A., & Chaudhary, N. S. (2024) · Current Enzyme Inhibition · doi:10.2174/0115734080296802240528073027 · Cited by 2
AI Devices in Neurology—Moving From Diagnosis to Prognosis
Hillis, J. M., Cliff, E. R. S., & Vokinger, K. N. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.3835 · Cited by 3
Pharmacotherapy for Alzheimer’s disease: what’s new on the horizon?
Khoury, R., Gallop, A., Roberts, K., Grysman, N., Lu, J., & Grossberg, G. T. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2097868 · Cited by 2
Invited Commentary: Radiologist's Role in Anti-Amyloid Therapy for Alzheimer Disease
Yu, F. F. (2023) · Radiographics · doi:10.1148/rg.230205 · Cited by 2
Phosphatidylinositol (PI) Lipids Modulate the Binding of Tau Fibrils on Lipid BilayersPreprint
Chowdhury, U. D., Paul, A., & Bhargava, B. L. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.20.558589 · Cited by 2
New Horizons in Studying the Cellular Mechanisms of Alzheimer’s Disease
Ehsani, S. (2022) · Future of business and finance · doi:10.1007/978-3-030-99838-7_4 · Cited by 3
Ackley, S. F., Flanders, M. D., Murchland, A. R., Chen, R., Wang, J., Shah, S., Huey, E. D., & Glymour, M. M. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70205 · Cited by 2
“While some argue that results from recent agents clearly demonstrate a causal role of amyloid in cognitive decline, 4,5 others speculate about possible non-amyloid mechanisms.”
Chaulagain, B., Gothwal, A., Mahanta, A. K., Jarajapu, Y. P. R., & Singh, J. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c01009 · Cited by 1
In the Slip Stream of Amyloid: The Tau and Tangle Hypothesis
Behl, C. (2023) · Springer eBooks · doi:10.1007/978-3-031-31570-1_12 · Cited by 1
Role of anandamide in Alzheimer's disease
Vera, D. M., & Tambaro, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19081-0.00014-7 · Cited by 1
Huang, Z., Merrihew, G. E., Larson, E. B., Park, J., Plubell, D. L., Fox, E. J., Montine, K. S., Keene, C. D., Zou, J., MacCoss, M. J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.09.511430 · Cited by 1
Maccioni, R., Travisan, C., Zerial, S., Wagener, A., Andrade‐Talavera, Y., Picciau, F., Grassi, C., Chen, G., Lemoine, L., Fisahn, A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.24.513473 · Cited by 1
Metadata
- Authors
- Selkoe, D. J.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Selkoe, Dennis J.
- ORCID
- Selkoe, Dennis J.
- Venue
- Science
- Published
- 2021-08-06
- Volume
- 373
- Issue
- 6555
- Pages
- 624-626
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3193092593
- Cited by
- 117
- References
- 15
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 20 · 2023: 31 · 2022: 40 · 2021: 6
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, anti-amyloid immunotherapy, disease-modifying therapy, amyloid-beta, treatment development
- MeSH terms
- Alzheimer Disease, Animals, Brain, Clinical Trials as Topic, Enzyme Inhibitors, Humans, Immunotherapy, Biomarkers, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Mice, Amyloid Precursor Protein Secretases, Plaque, Amyloid, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.